Commentary
Of chloroquine and COVID-19

https://doi.org/10.1016/j.antiviral.2020.104762Get rights and content

Highlights

  • In vitro data suggest that chloroquine inhibits SARS Cov-2 replication.

  • In past research, chloroquine has shown in vitro activity against many different viruses, but no benefit in animal models.

  • Chloroquine has been proposed several times for the treatment of acute viral diseases in humans without success.

  • The outcomes of some current clinical trials of chloroquine in China have been announced, without access to the data.

  • Peer review of the results and an independent assessment of the potential benefit for patients are essential.

Abstract

Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.

Keywords

SARS-CoV-2
COVID-19
2019-nCoV
Chloroquine
Antiviral

Cited by (0)

View Abstract